MNPR
Q4 2026 EPS Estimate
$-0.84
Nov 12, 2026 · Reports before open
FY2029E EPS$0.69
FY2030E EPS$3.92

Analyst Sentiment

Wall St. Consensus
Buy
14 analysts·Moderate coverage
70
Score
11 Buy (79%)3 Hold (21%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1179%
Hold
321%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$105.00
-7.1%
Consensus
$125.00
+10.6%
Bull
$133.00
+17.7%
12-Month Target Range14 analysts
$105.00$125.00$133.00
Current $113.04Consensus
Current Price
$113.04
Upside to Consensus
$11.96

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+3798.63%
EPS
FY2028
Rev+446.37%
EPS
FY2029
Rev+96.88%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$400,000$16M$85M$168M$290M
Low$257,252$4M$61M$108M$186M
High$594,628$29M$122M$249M$431M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-23M$-30M$-14M$5M$29M
Low$-38M$-52M$-55M$3M$16M
High$-10M$-8M$20M$8M$47M
EPS Avg$-2.78$-3.48$-1.90$0.69$3.92
Low$-5.18$-7.02$-7.38$0.37$2.10
High$-1.34$-1.09$2.64$1.13$6.39
Analysts (Rev / EPS)8 / 97 / 77 / 63 / 35 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$550,000$366,333$1M$5M$8M
Low$550,000$366,333$1M$5M$8M
High$550,000$366,333$1M$5M$8M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-7M$-9M$-8M$-9M$-9M$-17M
Low$-11M$-9M$-8M$-9M$-9M$-17M
High$-3M$-9M$-8M$-9M$-9M$-17M
EPS Avg$-0.77$-1.03$-0.98$-1.08$-1.03$-2.04
Low$-1.30$-1.03$-0.98$-1.08$-1.03$-2.04
High$-0.33$-1.03$-0.98$-1.08$-1.03$-2.04
Analysts (Rev / EPS) / 81 / 41 / 31 / 41 / 31 / 4

Earnings Surprises

Recent Analyst Actions

Aug 13, 2026Barclays
Monopar Therapeutics price target raised to $128 from $125 at Barclays
Target:$128.00
+11.4%from $114.90
Aug 13, 2026Cantor Fitzgerald
Monopar Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Target:$119.00
+3.6%from $114.90
Aug 12, 2026BTIG
Monopar Therapeutics price target raised to $133 from $117 at BTIG
Target:$133.00
+15.8%from $114.90
Jul 23, 2026UBS
Monopar Therapeutics (MNPR) PT Raised to $125 at H.C. Wainwright
Target:$125.00
+11.1%from $112.48
Jul 22, 2026H.C. Wainwright
Monopar price target raised to $125 from $105 at H.C. Wainwright
Target:$125.00
+11.0%from $112.63
Jun 30, 2026BTIG
Monopar Therapeutics (MNPR) PT Raised to $117 at BTIGMember Login
Target:$117.00
+23.7%from $94.56
Jun 29, 2026UBS
H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)
Target:$105.00
+19.8%from $87.68
Jun 2, 2026Piper Sandler
H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)
Target:$105.00
+63.0%from $64.40
Jan 9, 2026Morgan Stanley
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
Target:$115.00
+81.4%from $63.40
Nov 14, 2025Raymond James
Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform
Target:$123.00
+41.4%from $87.01
Oct 13, 2025Barclays
Monopar Therapeutics initiated with an Overweight at Barclays
Target:$125.00
+42.3%from $87.82
Oct 6, 2025Raymond James
Monopar Therapeutics price target raised to $142 from $80 at Raymond James
Target:$142.00
+42.9%from $99.39
Oct 2, 2025Oppenheimer
Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer
Target:$115.00
+35.7%from $84.73
Sep 29, 2025H.C. Wainwright
Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright
Target:$105.00
+37.0%from $76.63
Sep 25, 2025Chardan Capital
Monopar Therapeutics price target raised to $85 from $60 at Chardan
Target:$85.00
+16.9%from $72.69
Sep 25, 2025Piper Sandler
Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler
Target:$95.00
+30.7%from $72.69
Sep 24, 2025BTIG
Monopar Therapeutics price target raised to $104 from $87 at BTIG
Target:$104.00
+42.4%from $73.04
Sep 9, 2025BTIG
Monopar Therapeutics initiated with a Buy at BTIG
Target:$87.00
+93.6%from $44.93
Sep 2, 2025Raymond James
Monopar Therapeutics initiated with a Strong Buy at Raymond James
Target:$80.00
+135.8%from $33.93
Aug 26, 2025H.C. Wainwright
Monopar Therapeutics assumed with a Buy at H.C. Wainwright
Target:$70.00
+128.7%from $30.61
Nov 19, 2024UBS
Monopar Therapeutics (MNPR) PT Raised to $37 at Jones Trading
Target:$37.00
+94.6%from $19.01
Nov 11, 2024H.C. Wainwright
Monopar Therapeutics (MNPR) PT Raised to $22 at H.C. Wainwright
Target:$22.00
+39.2%from $15.81
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.